MMMNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
3M CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 20, 2026
$162.01−2.74 (-1.66%)
Close on Oct 19, 2026
- Market cap
- $84.63B
- P/E (TTM)
- 28.8
- Dividend yield
- 1.80%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
39.9%−8.5 pts over 5 years
Operating margin
18.6%−3.7 pts over 5 years
Net margin
13.0%−3.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1.5% | -1.6% | -5.0% | -1.9% | |
| Gross profit | -1.7% | -1.1% | -8.6% | -3.9% | |
| Operating income | -4.0% | +1.9% | -8.4% | -4.0% | |
| Net income | -22.1% | -17.4% | -9.8% | -3.9% | |
| EPS, diluted | -20.5% | -16.2% | -8.5% | -2.3% | |
| Free cash flow | +118.8% | -28.6% | -26.7% | -11.9% | |
| Dividend per share | -19.1% | -21.2% | -13.1% | -3.3% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 46.5% | 47.5% | 76.1% | |
| Return on assets | 15.4% | 11.8% | 8.4% | |
| Current ratio | 1.89 | 1.89 | 1.71 | |
| Debt to equity | 1.13 | 1.46 | 2.68 | |
| Net debt to EBITDA | 1.09× | 1.56× | 1.24× | |
| Interest coverage | 35.3× | 13.5× | 4.9× | |
| Inventory turnover | 4.4× | 4.0× | 4.1× | |
| Capex to revenue | 4.7% | 4.7% | 3.6% | |
| Diluted shares | 619M | 582M | 541M |
Where the cash went
Fiscal 2021 to 2025, five years combined
3M generated $23.85B from operations and spent $29.45B on capital expenditure, dividends and share buybacks. 24% of that went back into the business.
Generated
$23.85B
Used
$29.45B
Capital expenditure$7.06B24%Dividends$13.64B46%Share buybacks$8.75B30%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin13.0%
×Asset turnover0.64×
×Equity multiplier9.08×
=Return on equity, FY202576.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 13.0% | 0.64× | 9.08× | 76.1% |
| FY2024 | 17.0% | 0.54× | 10.46× | 96.5% |
| FY2023 | -28.4% | 0.51× | 4.97× | -71.6% |
| FY2022 | 22.1% | 0.56× | 3.14× | 38.8% |
| FY2021 | 16.7% | 0.75× | 3.38× | 42.4% |
| FY2020 | 16.9% | 0.70× | 4.01× | 47.5% |
| FY2019 | 14.1% | 0.79× | 4.09× | 45.5% |
| FY2018 | 16.3% | 0.88× | 3.49× | 50.1% |
| FY2017 | 15.3% | 0.89× | 3.24× | 44.4% |
| FY2016 | 16.8% | 0.92× | 3.03× | 46.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$3.25B
- Cash generatingOperating cash flow above zero$2.31B
- Return on assets improvedROA up on the prior year8.3% → 8.2%
- Earnings backed by cashOperating cash flow above net income$2.31B vs $3.25B
- Less leverageLong-term debt to assets fell27.9% → 29.0%
- Better liquidityCurrent ratio rose1.41 → 1.71
- No dilutionShare count did not rise552M → 541M
- Gross margin improvedGross margin up on the prior year41.21% → 39.91%
- More efficientAsset turnover rose0.49 → 0.63